# A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors

> **NCT02210663** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 16 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** veliparib (ABT-888)

## Key facts

- **NCT ID:** NCT02210663
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2016-01
- **Final completion:** 2016-07
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2018-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02210663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02210663, "A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02210663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*